Dermbits

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions

Are we sometimes optimizing for BSA instead of optimizing for the patient’s lived experience?
2:42
Jun 1, 2026Psoriasis

Are we sometimes optimizing for BSA instead of optimizing for the patient’s lived experience?

-

What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal?
0:58
May 7, 2026Psoriasis

What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal?

-

In patients who have failed or discontinued biologics, when does apremilast reenter consideration?
1:12
May 7, 2026Psoriasis

In patients who have failed or discontinued biologics, when does apremilast reenter consideration?

-

How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either?
1:28
May 7, 2026Psoriasis

How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either?

-

Are there particular comorbidity profiles where apremilast feels especially appropriate?
1:40
May 7, 2026Psoriasis

Are there particular comorbidity profiles where apremilast feels especially appropriate?

-

Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics?
0:38
May 7, 2026Psoriasis

Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics?

-

What lifestyle or occupational factors make oral therapy particularly appealing?
1:26
May 7, 2026Psoriasis

What lifestyle or occupational factors make oral therapy particularly appealing?

-

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?
1:25
Apr 13, 2026Psoriasis

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

-

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?
1:51
Apr 13, 2026Psoriasis

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

-

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?
2:04
Apr 13, 2026Psoriasis

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

-

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?
2:34
Apr 13, 2026Psoriasis

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

-

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?
2:55
Apr 13, 2026Psoriasis

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

-

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?
1:29
Apr 13, 2026Psoriasis

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

-

When apremilast first launched, how was it positioned, and what do we understand differently now?
1:55
Apr 13, 2026Psoriasis

When apremilast first launched, how was it positioned, and what do we understand differently now?

-

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?
0:42
Mar 3, 2026Psoriasis

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

-

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?
0:44
Mar 3, 2026Psoriasis

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

-

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?
0:36
Mar 3, 2026Psoriasis

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

-

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?
0:41
Mar 3, 2026Psoriasis

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

-

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?
1:04
Mar 3, 2026Psoriasis

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

-

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?
0:51
Mar 3, 2026Psoriasis

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

-

Are there specific patient populations who are at higher risk for adverse effects from ixekizumab?
0:35
Nov 1, 2024Psoriasis

Are there specific patient populations who are at higher risk for adverse effects from ixekizumab?

-

What are the considerations for using ixekizumab in patients with a history of serious infections?
0:38
Nov 1, 2024Psoriasis

What are the considerations for using ixekizumab in patients with a history of serious infections?

-

Does patient weight impact the dosing and efficacy of ixekizumab?
0:20
Nov 1, 2024Psoriasis

Does patient weight impact the dosing and efficacy of ixekizumab?

-

What strategies can be used to taper ixekizumab in patients with sustained remission?
0:36
Nov 1, 2024Psoriasis

What strategies can be used to taper ixekizumab in patients with sustained remission?

-